康德莱收盘上涨1.10%，滚动市盈率16.76倍，总市值36.12亿元

Core Insights - The company, Kangdelai, closed at 8.27 yuan on July 24, with a 1.10% increase, resulting in a rolling PE ratio of 16.76 times and a total market capitalization of 3.612 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 54.56 times and a median of 37.54 times, Kangdelai ranks 37th [1] - As of March 31, 2025, the number of shareholders in Kangdelai is 25,817, a decrease of 822 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Kangdelai specializes in the research, production, sales, and service of medical devices, including medical puncture needles and infusion devices [1] - The main product categories include puncture care, infusion catheters, indwelling infusion, puncture intervention, medical aesthetics, drug packaging materials, animal medical devices, insulin delivery, specimen collection, and active medical devices [1] - The company has established a municipal-level enterprise technology center in Shanghai and has set up a provincial-level puncture medical device research institute in Zhejiang [1] Financial Performance - In the latest quarterly report for Q1 2025, Kangdelai reported a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.7042 million yuan, reflecting a year-on-year increase of 0.28% [1] - The sales gross margin for the company stands at 32.02% [1]